Skip to main content
OpenTrials
Completed

NCT Number: NCT01443403

A Study of Naldemedine (S-297995) for the Treatment of Opioid-Induced Constipation in Adults With Non-Malignant Chronic Pain Receiving Opioid Therapy

The purpose of this study is to determine efficacy and safety of naldemedine for the treatment of opioid-induced constipation in adults with non-malignant chronic pain receiving opioid therapy for ≥ 3 months.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Opioid-induced Constipation Chemically-Induced Disorders Constipation Mental Disorders Narcotic-Related Disorders Pathological Conditions, Signs and Symptoms Signs and Symptoms Signs and Symptoms, Digestive Substance-Related Disorders

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Shionogi Research Site, Phoenix, Arizona, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects aged 18 years or older at time of informed consent with non-malignant chronic pain experiencing opioid-induced constipation
  • Subjects with < 3 spontaneous bowel movements a week and experiencing bowel symptoms
  • Subjects receiving chronic opioid therapy due to non-malignant pain for ≥ 3 months

Exclusion criteria

  • Evidence of clinically significant gastrointestinal disease
  • History of chronic constipation prior to starting analgesic medication or any potential non-opioid cause of bowel dysfunction that may be a major contributor to the constipation
  • Severe constipation that has not been appropriately managed such that the subject is at immediate risk of developing serious complications of constipation

Treatment and study plan

Placebo

Drug

Matching placebo tablets administered orally once a day.

Naldemedine

Drug

Naldemedine tablets administered orally once a day.

Other names: S 297995, Symproic®

Primary outcomes

  1. Change From Baseline to Last 2 Weeks of the Treatment Period in the Number of Spontaneous Bowel Movements Per Week

    Time frame: Baseline (2 weeks prior to randomization) and the last 2 weeks of treatment (Weeks 3 to 4 for participants who completed the 28-day treatment period)

    Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.

    A spontaneous bowel movement was defined as a bowel movement unassisted by rescue medication (laxative or enema) taken within the 24 hours preceding the bowel movement. Baseline was defined as the average number of SBMs per week during the 2 weeks prior to randomization. The number of SBMs per week in the last 2 weeks of treatment is defined as the average number of SBMs per week recorded in the diary for the 14 days prior to the last dose of study drug.

Secondary outcomes

  1. Change From Baseline to Weeks 1, 2, 3, and 4 in the Number of Spontaneous Bowel Movements Per Week

    Time frame: Baseline and Weeks 1, 2, 3, and 4

    Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.

    A spontaneous bowel movement was defined as a bowel movement unassisted by rescue medication (laxative or enema) taken within the 24 hours preceding the bowel movement. Baseline was defined as the average number of SBMs per day during the 2 weeks prior to randomization.

  2. Change From Baseline to the Last 2 Weeks of the Treatment Period in the Number of Bowel Movements (BMs) Per Week

    Time frame: Baseline and the last 2 weeks of treatment (Weeks 3 to 4 for participants who completed the 28-day treatment period)

    Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.

    A BM was defined as all bowel movements observed irrespective of the use of a laxative agent.

  3. Change From Baseline to Weeks 1, 2, 3, and 4 in the Number of Bowel Movements Per Week

    Time frame: Baseline and Weeks 1, 2, 3, and 4

    Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.

    A BM was defined as all bowel movements observed irrespective of the use of a laxative agent.

  4. Change From Baseline to the Last 2 Weeks of the Treatment Period in the Number of Complete Bowel Movements (CBMs) Per Week

    Time frame: Baseline and the last 2 weeks of treatment (Weeks 3 to 4 for participants who completed the 28-day treatment period)

    Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.

    A complete BM (CBM) was defined as a BM where the participant answered 'Yes' to the following question: 'Did you have a feeling of complete emptying after the bowel movement?'

  5. Change From Baseline to Weeks 1, 2, 3, and 4 in the Number of Complete Bowel Movements Per Week

    Time frame: Baseline and Weeks 1, 2, 3, and 4

    Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.

    A complete BM (CBM) was defined as a BM where the participant answered 'Yes' to the following question: 'Did you have a feeling of complete emptying after the bowel movement?'

  6. Change From Baseline to the Last 2 Weeks of the Treatment Period in the Number of Complete Spontaneous Bowel Movements (CSBMs) Per Week

    Time frame: Baseline and the last 2 weeks of treatment (Weeks 3 to 4 for participants who completed the 28-day treatment period)

    Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.

    A CSBM was defined as a spontaneous BM which was accompanied by the feeling of complete evacuation.

  7. Change From Baseline to Weeks 1, 2, 3, and 4 in the Number of Complete Spontaneous Bowel Movements Per Week

    Time frame: Baseline and Weeks 1, 2, 3, and 4

    Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.

    A CSBM was defined as a spontaneous BM which was accompanied by the feeling of complete evacuation.

  8. Percentage of Participants With an SBM Response in the Last 2 Weeks of the Treatment Period

    Time frame: Baseline and the last 2 weeks of treatment (Weeks 3 to 4 for participants who completed the 28-day treatment period)

    Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.

    An SBM responder was defined as a participant whose frequency of SBMs within the last 2 weeks of the treatment period was 3 times or more per week and who had an average increase in the frequency of SBMs from baseline of 1 or more per week.

  9. Percentage of Participants With an SBM Response at Weeks 1, 2, 3 and 4

    Time frame: Baseline and Weeks 1, 2, 3, and 4

    Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.

    An SBM responder was defined as any participant whose frequency of SBM per week during the treatment period was 3 times or more per week, and who had an average increase from baseline of 1 or more per week.

  10. Percentage of Participants With a CSBM Response in the Last 2 Weeks of the Treatment Period

    Time frame: Baseline and the last 2 weeks of treatment (Weeks 3 to 4 for participants who completed the 28-day treatment period)

    Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.

    A CSBM responder was defined as a participant whose frequency of CSBMs within the last 2 weeks of the treatment period was 3 times or more per week and who had an average increase in the frequency of CSBMs from baseline of 1 or more per week.

  11. Percentage of Participants With a CSBM Response at Weeks 1, 2, 3, and 4

    Time frame: Baseline and Weeks 1, 2, 3, and 4

    Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.

    A CSBM responder was defined as a participant whose frequency of CSBMs during the treatment period was 3 times or more per week and who had an average increase in the frequency of CSBMs from baseline of 1 or more per week.

  12. Change From Baseline to the Last 2 Weeks of the Treatment Period in Number of Days Per Week With SBMs

    Time frame: Baseline and the last 2 weeks of treatment (Weeks 3 to 4 for participants who completed the 28-day treatment period)

    Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.

    An SBM is defined as a bowel movement unassisted by rescue medication (laxative or enema) taken within the 24 hours preceding the bowel movement.

  13. Change From Baseline to Weeks 1, 2, 3 and 4 in Number of Days Per Week With SBMs

    Time frame: Baseline and Weeks 1, 2, 3, and 4

    Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.

    An SBM is defined as a bowel movement unassisted by rescue medication (laxative or enema) taken within the 24 hours preceding the bowel movement.

  14. Change From Baseline to the Last 2 Weeks of the Treatment Period in Number of Days Per Week With CSBMs

    Time frame: Baseline and the last 2 weeks of treatment (Weeks 3 to 4 for participants who completed the 28-day treatment period)

    Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.

    A CSBM was defined as a spontaneous BM which was accompanied by the feeling of complete evacuation.

  15. Change From Baseline to Weeks 1, 2, 3 and 4 in Number of Days Per Week With CSBMs

    Time frame: Baseline and Weeks 1, 2, 3, and 4

    Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.

    A CSBM was defined as a spontaneous BM which was accompanied by the feeling of complete evacuation.

  16. Time to the First Spontaneous Bowel Movement

    Time frame: 28 days

    Time to the first SBM was defined as the time to the first SBM after the initial administration of study drug. Participants who withdrew from the study before an SBM was observed or had no SBM during the treatment period were treated as censored.

  17. Time to the First Complete Spontaneous Bowel Movement

    Time frame: 28 days

    Time to the first CSBM was defined as the time to the first CSBM after the initial administration of study drug. Participants who withdrew from the study before a CSBM was observed or had no CSBM during the treatment period were treated as censored.

  18. Percentage of Participants With SBMs Within 4, 8, 12, and 24 Hours After the Initial Administration of Study Drug

    Time frame: 4, 8, 12, and 24 hours

    The percentage of participants who experienced at least one SBM within 4, 8, 12, and 24 hours after the initial administration of study drug and before the second administration.

  19. Percentage of Participants With CSBMs Within 4, 8, 12, and 24 Hours After the Initial Administration of Study Drug

    Time frame: 4, 8, 12, and 24 hours

    The percentage of participants who experienced at least one CSBM within 4, 8, 12, and 24 hours after the initial administration of study drug and before the second administration.

  20. Change From Baseline to the Last 2 Weeks of the Treatment Period in Number of SBMs Per Week Rated as 3 or 4 on the Bristol Stool Scale

    Time frame: Baseline and the last 2 weeks of treatment (Weeks 3 to 4 for participants who completed the 28-day treatment period)

    Consistency of BMs was measured using the Bristol Stool Scale, according to the following: 1 = separate hard lumps like nuts; 2 = sausage shaped but lumpy; 3 = like a sausage, but with cracks on its surface; 4 = like a sausage or a snake, smooth and soft; 5 = soft blobs and with clear-cut edges; 6 = floppy pieces with ragged edges/mushy stool; 7 = watery, no solid pieces, entirely liquid.

  21. Change From Baseline to Weeks 1, 2, 3, and 4 in Number of SBMs Rated as 3 or 4 on the Bristol Stool Scale Per Week

    Time frame: Baseline and Weeks 1, 2, 3, and 4

    Consistency of BMs was measured using the Bristol Stool Scale, according to the following: 1 = separate hard lumps like nuts; 2 = sausage shaped but lumpy; 3 = like a sausage, but with cracks on its surface; 4 = like a sausage or a snake, smooth and soft; 5 = soft blobs and with clear-cut edges; 6 = floppy pieces with ragged edges/mushy stool; 7 = watery, no solid pieces, entirely liquid.

  22. Change From Baseline to the Last 2 Weeks of the Treatment Period in Number of SBMs Per Week With no Straining

    Time frame: Baseline and the last 2 weeks of treatment (Weeks 3 to 4 for participants who completed the 28-day treatment period)

    Straining during BMs was graded using the following scale: 0 = No straining; 1 = Mild straining; 2 = Moderate; 3 = Severe; 4 = Very Severe. A BM without straining was defined as a BM with a straining score of 0 or 1.

  23. Change From Baseline to Weeks 1, 2, 3, and 4 in the Number of SBMs Per Week Without Straining

    Time frame: Baseline and Weeks 1, 2, 3, and 4

    Straining during BMs was graded using the following scale: 0 = No straining; 1 = Mild straining; 2 = Moderate; 3 = Severe; 4 = Very Severe. A BM without straining is defined as a BM with a straining score of 0 or 1.

  24. Change From Baseline to the Last 2 Weeks of the Treatment Period in Number of False Start BMs Per Week

    Time frame: Baseline and the last 2 weeks of treatment (Weeks 3 to 4 for participants who completed the 28-day treatment period)

    Participants completed a daily Bowel Movement and Constipation Assessment Diary to record information about bowel movements and constipation.

    A false start was defined as any attempted, but unsuccessful bowel movement (no solid or liquid fecal material was excreted).

  25. Change From Baseline to the Last 2 Weeks of the Treatment Period in Rescue Use of Laxative Agents Per Week

    Time frame: Baseline and the last 2 weeks of treatment (Weeks 3 to 4 for participants who completed the 28-day treatment period)

    Participants were asked how many doses of rescue laxative medication they had taken within the past 24 hours as part of the Bowel Movement and Constipation Assessment Diary (BMCA).

  26. Mean Rescue Laxative Use Per Week During the Treatment Period

    Time frame: Weeks 1 to 4

    Participants were asked how many doses of rescue laxative medication they had taken within the past 24 hours as part of the Bowel Movement and Constipation Assessment Diary (BMCA).

  27. Change From Baseline to the Last 2 Weeks of the Treatment Period in Abdominal Bloating

    Time frame: Baseline and the last 2 weeks of treatment (Weeks 3 to 4 for participants who completed the 28-day treatment period)

    Participants were asked to rate their abdominal bloating for the past 24 hours on a scale of 0 to 4, where 0 = Absent; 1 = Mild; 2 = Moderate; 3 = Severe; 4 = Very Severe.

  28. Change From Baseline to Weeks 1, 2, 3, and 4 in Abdominal Bloating

    Time frame: Baseline and Weeks 1, 2, 3, and 4

    Participants were asked to rate their abdominal bloating for the past 24 hours on a scale of 0 to 4, where 0 = Absent; 1 = Mild; 2 = Moderate; 3 = Severe; 4 = Very Severe.

  29. Change From Baseline to the Last 2 Weeks of the Treatment Period in Abdominal Discomfort

    Time frame: Baseline and the last 2 weeks of treatment (Weeks 3 to 4 for participants who completed the 28-day treatment period)

    Participants were asked to rate their abdominal discomfort for the past 24 hours on a scale from 0 to 4, where 0 = Absent; 1 = Mild; 2 = Moderate; 3 = Severe; 4 = Very Severe.

  30. Change From Baseline to Weeks 1, 2, 3, and 4 in Abdominal Discomfort

    Time frame: Baseline and Weeks 1, 2, 3, and 4

    Participants were asked to rate their abdominal discomfort for the past 24 hours on a scale from 0 to 4, where 0 = Absent; 1 = Mild; 2 = Moderate; 3 = Severe; 4 = Very Severe.

  31. Subject Global Satisfaction at End of Treatment

    Time frame: Day 29, or at early termination

    On day 29 (or at early termination), participants were asked about their degree of satisfaction with constipation and abdominal symptoms from the start of study drug dosing to Day 28 (or early termination visit). The grades were as follows: 1, markedly worsened; 2, moderately worsened; 3, slightly worsened; 4, unchanged; 5, slightly improved; 6, moderately improved; and 7, markedly improved.

  32. Maximum Observed Plasma Concentration (Cmax) of Naldemedine and Metabolite Nor-S-297995

    Time frame: Day 1 and Day 28 predose and 1, 2, 4, 8, and 24 hours postdose

    Pharmacokinetic blood samples for naldemedine (S-297995) and its metabolite, Nor-S-297995, were collected from a subset of participants at selected study sites on Day 1 and in a further subset on Day 28.

  33. Time to Maximum Concentration (Tmax) of Naldemedine and Metabolite Nor-S-297995

    Time frame: Day 1 and Day 28 predose and 1, 2 , 4, 8, and 24 hours postdose

    Pharmacokinetic blood samples for naldemedine (S-297995) and its metabolite, Nor-S-297995, were collected from a subset of participants at selected study sites on Day 1 and in a further subset on Day 28.

  34. Area Under the Concentration-time Curve From Hour 0 to the Time Point of the Last Measurable Concentration Within the Dose Interval (AUC0-τ)

    Time frame: Day 1 and Day 28 predose and 1, 2 , 4, 8, and 24 hours postdose

    Pharmacokinetic blood samples for naldemedine (S-297995) and its metabolite, Nor-S-297995, were collected from a subset of participants at selected study sites on Day 1 and in a further subset on Day 28.

  35. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    Time frame: From first dose of study drug through 28 days after the last dose of study treatment (up to 57 days).

    Treatment-emergent adverse events (TEAEs) were adverse events that occurred after the first dose of study drug.

    Treatment-related TEAEs were defined as TEAEs that were considered by the Investigator to be definitely, probably, or possibly related to study drug.

Sponsors and collaborators

Lead sponsor

Shionogi

Industry

Registry information

Official study title

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of S-297995 for the Treatment of Opioid-Induced Constipation in Subjects With Non-Malignant Chronic Pain Receiving Opioid Therapy

Important dates

Study start
2011
Primary completion
2012
Study completion
2012
First posted
Sep 29, 2011
Registry last updated
Jun 26, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.